Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Overview
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: January 2024
Detailed Description
This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.
Clinical Trial Outcome Measures
Primary Measures
- Incidence of driver gene abnormalities
- Time Frame: from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months
- the incidence of driver gene abnormalities by fixed gene testing technology
Secondary Measures
- objective response rate
- Time Frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
- the total proportion of patients with complete response (CR) and partial response (PR)
- 5-year overall survival
- Time Frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years
- from the date of first patient was included to the date of death by any cause
- Clinicopathological Characteristics
- Time Frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
- study data on clinicopathological characteristics related to incidence of driver gene abnormalities
Participating in This Clinical Trial
Inclusion Criteria
1. Diagnosed as lymphoma (according to WHO 2017 classification criteria) 2. Life expectancy no less than 3 months 3. Agreeing to sign the written informed consents Exclusion Criteria:
1. Other malignant tumor history or active malignant tumor need be treated 2. Researchers determine unsuited to participate in this trial
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Henan Cancer Hospital
- Provider of Information About this Clinical Study
- Principal Investigator: Yanyan Liu, Director – Henan Cancer Hospital
- Overall Official(s)
- Yanyan Liu, M.D. Ph.D, Study Director, Henan Cancer Hospital
- Overall Contact(s)
- Yanyan Liu, M.D. Ph.D, +8613818176375, yyliu@zzu.edu.cn
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.